Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
Clinical trial NCT03531827 · TERMINATED
Trial details
- NCT number
- NCT03531827
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-26
- Primary completion
- 2021-05-15
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.